Nature Communications | Article | open
Immunotherapy is the most promising new cancer treatment of the last years. By re-awakening and enhancing the immune system to fight cancer, such strategies have achieved impressive clinical responses. However, many cancer types still do not respond to immunotherapy and many patients do not receive durable benefit, eventually developing resistance.
Broadening the clinical applicability of cancer immunotherapy requires a deep understanding of the molecular and genetic mechanisms that influence whether cancer cells resist or respond. With the ultimate goal to expand the benefits of immunotherapy and find actionable strategies to combat therapeutic resistance, an increasing number of studies are now testing in pre-clinical models different combinations with other therapies, including targeted therapies, and nanoparticle-based approaches. Furthermore, significant efforts are underway to identify reliable predictive biomarkers of response and resistance to immunotherapy such as checkpoint inhibitors.
Our collection, which has been curated by the Cancer editorial team at Nature Communications, brings together cutting-edge important research in the field of cancer immunotherapy published in our journal. The collection is divided into four research areas; mechanisms of resistance, combination therapies, nanocomplex, and predictors of response. We aim to provide insights on future directions for new therapeutic development in this important area, recognizing the value of bench-based and pre-clinical studies as a first step to translation to the clinic and patient care.